By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team
Few lab results generate as many questions—and as much unnecessary worry—as the AMH test. Patients arrive at our office every week clutching a printed number, convinced it is a verdict on their ability to become a mother. The reality is more nuanced and, for most people, more encouraging: anti-Müllerian hormone is a genuinely useful measure of the ovarian reserve—the estimated supply of remaining eggs—but it is one data point among several, it says nothing by itself about egg quality, and it does not determine whether you will get pregnant. This guide explains what AMH actually measures, what the numbers mean (and don’t mean), how the rest of the reserve workup fits together, and what treatment and preservation options exist when the number runs low—for patients here in Torrance and the South Bay.
1. Why Ovarian Reserve Matters
Every woman is born with a fixed supply of eggs, and that supply declines steadily across life—rapidly before birth, gradually through childhood, and in a measurable downward slope from the mid-twenties onward, steepening again in the late thirties. Ovarian reserve is the clinical shorthand for how large that remaining supply appears to be at a given moment. It matters for two practical reasons. First, reserve helps predict how the ovaries will respond to fertility treatment—how many eggs a stimulation cycle is likely to yield, which shapes protocol choices and expectations. Second, a reserve assessment turns vague anxiety into a concrete plan: instead of wondering, you get numbers, a timeline, and options such as fertility preservation discussed at the right moment rather than years too late.
What reserve is not is a fertility scorecard. The World Health Organization (WHO) estimates that roughly 1 in 6 adults worldwide experiences infertility at some point, and its causes are distributed across both partners, anatomy, hormones, and plain chance—not egg counts alone. Many women with low readings conceive without difficulty, and many with reassuring numbers still need help for other reasons. Hold that balance throughout this guide: reserve testing is a planning tool, not a prophecy.
2. What Is Ovarian Reserve?
Ovarian reserve refers to the pool of resting follicles in the ovaries—each follicle containing an immature egg—that could still potentially be recruited in the future. Before birth the ovaries hold several million follicles; by puberty roughly a few hundred thousand remain; and only a few hundred to a thousand will ever ovulate, because the vast majority are lost to a natural process of attrition that continues regardless of pregnancy, birth control, or lifestyle. Each month, a cohort of follicles is recruited from this pool, usually only one reaching full maturity and releasing an egg—the rest dissolving away.
Two distinctions matter enormously in how you read any reserve result. The first is quantity versus quality: reserve tests estimate the number of remaining follicles, while egg quality—driven overwhelmingly by age at the chromosomal level—is a separate property that no blood test measures directly. The second is reserve versus function: a woman with a modest reserve and regular ovulation can be more fertile month-to-month than a woman with a large reserve whose ovulation is disrupted, as is common in PCOS. This is why reserve testing is always interpreted alongside your cycle history, age, ultrasound findings, and a partner’s semen analysis—never in isolation.
3. What Is AMH and Where Does It Come From?
Anti-Müllerian hormone (AMH) is a protein produced by the granulosa cells of small growing follicles in the ovaries—specifically the preantral and small antral follicles in the earliest visible stages of development. Because these early follicles represent the recruiting pool that stimulation treatments draw from, the amount of AMH circulating in blood serves as a convenient window into the size of that pool: more small follicles at work, more AMH produced; fewer, less.
AMH has two properties that make it especially practical for fertility care. It is relatively stable across the menstrual cycle, meaning it can be measured on any day of the cycle—unlike FSH and estradiol, which must be drawn in the first few days. And it changes slowly, declining gradually with age rather than swinging cycle to cycle, so a single value provides a reasonably current picture that remains useful for months. What AMH is not: it does not control ovulation, it is not a hormone whose “levels” you supplement, and it is not a measure of how well an egg will fertilize or become a baby. It is a census, not a quality inspection. The MedlinePlus AMH test overview offers a plain-language summary consistent with this framing.
4. The AMH Blood Test: What to Expect
The test itself is simple: a standard blood draw, usually returning results within a few days. Because AMH does not fluctuate much across the cycle, the draw can happen on any cycle day, and it does not require fasting or timing around ovulation. Hormonal birth control can modestly lower measured AMH in some studies, so it is worth telling your physician what you are taking so the result is read in context. At a first fertility consultation, AMH is typically ordered alongside day-3 FSH and estradiol, thyroid and prolactin screening, and a transvaginal ultrasound for the antral follicle count described in Section 6.
For planning purposes only: in the U.S., an AMH test commonly costs in the neighborhood of $100–$200 when billed separately—a typical industry range that varies by laboratory and insurance, not a quote from Incinta. Many insurance plans cover it as part of an infertility workup. The greater “cost” for most patients is interpretive: an unexplained number and an internet full of alarming anecdotes. Bring the result to a physician rather than to a search engine—the same value can carry very different meaning at age 27 versus 38, or alongside an ultrasound that shows a healthy follicle cohort.
5. What Do AMH Numbers Mean?
AMH is reported in nanograms per milliliter (ng/mL), and here is the honest headline: reference ranges vary between assays and laboratories, so the same blood sample can read slightly different values at different facilities. Always interpret your number against the range printed by the lab that ran it and in discussion with your physician. With that caveat, commonly published population data—including the NHANES reference study by Seifer and colleagues published in Fertility and Sterility in 2011—give a broad picture of typical values across reproductive ages:
- Below roughly 1.0–1.2 ng/mL: often described as consistent with diminished ovarian reserve—fewer follicles likely to respond to stimulation.
- Roughly 1.0–3.0 ng/mL: a common range through the core reproductive years, with values trending gradually lower as age advances.
- Above roughly 4–5 ng/mL: frequently seen in PCOS, reflecting an enlarged pool of small resting follicles—not automatically “superfertility.”
Three framing rules keep these numbers honest. First, they are population-level reference ranges, not a diagnosis for any individual—the clinical meaning of an AMH of 0.9 differs sharply between a 26-year-old with regular cycles and a 39-year-old planning IVF. Second, no AMH value predicts whether a natural cycle will succeed this year; the research on that question is covered in Section 7. Third, AMH is one input in the workup—an ultrasound-based antral follicle count and your age often add as much or more information, which is why no responsible physician makes pronouncements from a single blood value.
6. The Complete Reserve Workup: AMH Is One Piece
A proper ovarian reserve assessment combines several imperfect instruments, because each captures a different slice of the picture:
- AMH blood test: cycle-day-independent, reflects the pool of small growing follicles, useful for predicting stimulation response.
- Antral follicle count (AFC): a transvaginal ultrasound, usually early in the cycle, counting follicles roughly 2–10 mm across both ovaries. AFC is a real-time census of recruitable follicles and, together with AMH, forms the backbone of modern reserve assessment.
- Day-2 to day-4 FSH and estradiol: early-cycle FSH rises as the brain works harder to recruit follicles from a shrinking pool; an elevated value is another marker of diminishing reserve, though it fluctuates cycle to cycle more than AMH does.
- Age: the least glamorous variable and the most powerful one. Age integrates both quantity and quality decline and anchors every treatment recommendation, as Section 10 explains.
- History: prior ovarian surgery (see our endometriosis guide), chemotherapy or pelvic radiation, smoking, and family history of early menopause all re-weight how any number is interpreted.
When results disagree—an AMH of 1.8 with an AFC of 6, or vice versa—physicians read the pattern, not the outlier: age and history break the tie. The output of a good workup is not a grade but a response forecast: likely a strong responder, a normal responder, or a low responder—which directly shapes medication choices, retrieval expectations, and whether accumulating embryos across more than one cycle is worth discussing.
7. What AMH Can—and Cannot—Predict
Being precise about AMH’s predictive reach is the difference between useful information and needless fear. What AMH does predict reasonably well: how the ovaries will respond to stimulation medications in IVF—published materials from the American Society for Reproductive Medicine (ASRM) and the broader literature consistently show AMH and AFC correlating with the number of eggs retrieved. A low value flags the possibility of a modest response, cycle cancellation risk, or the need for adjusted protocols; a high value flags strong response and the need to manage overstimulation risk.
What AMH does not predict: whether you will conceive naturally, or on any particular timeline. The strongest single test of this came from the Danish STELLEC study (Hvidman and colleagues, published in CMAJ in 2021), which followed thousands of women aged 30–40 with no infertility history: a low AMH was not associated with reduced probability of spontaneous pregnancy over the study period, and a high AMH did not guarantee faster conception. Fecundability, it turns out, depends on ovulation, tubes, sperm, intercourse timing, and chance far more than on follicle census numbers.
And the most common misconception of all: AMH is not a measure of egg quality. A 33-year-old with an AMH of 0.8 generally has eggs of typical 33-year-old quality—fewer of them, but not worse ones. Quality declines with age, which is why age—not AMH—anchors miscarriage risk and embryo genetics discussions (see our PGT guide). The practical summary: use AMH to plan how to treat, not to predict whether treatment or time will work.
8. Low AMH: What It Means—and What It Doesn’t
A low AMH reading usually means the pool of recruitable follicles is smaller than typical for your age. Common contributors include: age itself (the dominant factor); genetics, including family patterns of early menopause; prior ovarian surgery—notably excision of endometriomas, which is documented in published studies to measurably reduce AMH (see our endometriosis guide); chemotherapy or pelvic radiation; smoking, which is associated with lower AMH in population studies; and occasionally endometriosis itself or an aggressive surgical history on the ovaries. Some low values simply reflect assay variation or a naturally low-normal position in the population distribution.
What a low value does not mean: that you cannot conceive, that your eggs are poor quality, or that pregnancy must happen through aggressive intervention immediately. Many women with low AMH ovulate regularly and conceive spontaneously; others need modest help; some need IVF for reasons unrelated to the number. What low AMH genuinely changes is the value of time and planning: it argues for a structured evaluation rather than open-ended waiting, and for candid conversations about how long to try before escalating—decisions that weigh far more heavily when the pool is small and age is advancing. The right response to a low number is a good plan, not panic.
9. High AMH and PCOS: The Other Side of the Coin
At the opposite end of the scale, elevated AMH is a hallmark of polycystic ovary syndrome: the arrested small follicles that characterize PCOS produce AMH, so values of two to three times the average are common in that population. Reading a high value correctly requires the same discipline as reading a low one. High AMH does not mean extraordinary fertility—PCOS often coexists with irregular or absent ovulation, so a large pool that never releases eggs is not an advantage month to month. What high AMH genuinely signals is a predictable treatment dynamic: PCOS patients tend to respond vigorously to stimulation medications, producing many eggs—and carrying a correspondingly elevated risk of ovarian hyperstimulation syndrome (OHSS) if protocols are not managed carefully.
That risk is manageable with modern safeguards—GnRH-antagonist protocols, agonist triggers, and freezing all embryos rather than transferring fresh—covered in detail in our PCOS guide. The takeaway is symmetrical: a high AMH calls for a plan that harnesses the strong response while controlling overstimulation, and a low AMH calls for a plan that maximizes efficiency within a smaller pool. Neither number is good or bad news on its own; both are inputs to a strategy.
10. Age and Fertility: The Bigger Picture Around AMH
Any AMH conversation is incomplete without the age context it lives inside. Fertility in women declines gradually through the twenties and early thirties, more noticeably from the mid-thirties, and more steeply again after the late thirties—guidance from ACOG and ASRM frames age 35 as the point where evaluation after 6 months of trying (rather than 12) becomes reasonable. The decline reflects both the shrinking pool AMH tracks and the rising share of chromosomally abnormal eggs—which is why embryo genetic testing conversations intensify with age even when reserve numbers look reassuring. For a concrete, age-stratified view of treatment outcomes, our complete IVF guide for Torrance walks through the national data published by the CDC.
AMH fits into this picture as an individualized speedometer on top of the population clock: two 36-year-olds can have materially different reserves, and testing distinguishes them in a way age alone cannot. That is also the logic behind checking AMH in women who are not yet trying—a single value, interpreted with an ultrasound, gives someone in her late twenties or early thirties a sense of her own trajectory and a basis for deciding whether freezing eggs now is prudent planning or unnecessary expense. Neither the population curve nor the personal number is destiny—but together they make timing a decision instead of a guess.
11. IVF Planning When Reserve Is Low
When reserve is genuinely diminished and treatment is indicated, IVF is often the most efficient path—not because it makes more eggs, but because it uses each retrieved egg to its fullest and gives the laboratory direct control over fertilization and embryo culture. Low-responder protocols are a genuine subspecialty: stimulation plans are individualized using your AMH, AFC, age, and prior response, and common adaptations include antagonist protocols with tailored dosing, microdose flare approaches designed to recruit harder-starting follicles, and—for some patients—embryo banking across consecutive cycles, accumulating embryos over two or more retrievals rather than expecting a single cycle to produce a large cohort. Each approach has trade-offs in cost, time, and burden, and none guarantees a specific outcome; the honest framework is efficiency per unit of time, not promises.
Two related decisions deserve equal candor. First, IUI has a narrow window in low-reserve patients: per-cycle odds are modest at baseline and the pool constrains how much stimulation can safely add, so many physicians move to IVF sooner—particularly with age—rather than spending months on lower-yield cycles. Second, embryo genetic testing interacts with reserve: PGT-A requires embryos to biopsy, and a low-responder may generate only a handful—so whether to test each small cohort or transfer untested embryos is a genuine judgment call your physician should walk through with real numbers from your cycle, not a default. And for some patients, physicians also outline other family-building paths in full, so the plan reflects your values rather than an algorithm’s.
12. Fertility Preservation: Freezing Eggs Before Reserve Declines
If the conclusion of a reserve evaluation is “the pool is smaller than typical for your age, and pregnancy is not on the table yet,” the strategic move is often egg freezing—harvesting and vitrifying eggs while they are younger, before the pool (and quality) decline further. AMH is central to this planning: it forecasts how many eggs a freezing cycle is likely to yield, which determines whether one cycle suffices or a second is advisable to reach a sensible target. Published outcome data generally suggest that eggs frozen in the twenties and early thirties carry materially better future-odds math than those frozen later—which is precisely why a low-for-age AMH reading at 28 or 31 is a prompt for a timely conversation, not for despair.
The boundaries, stated as always: frozen eggs are not a guarantee of a future baby. Outcomes depend on age at freezing, the number stored, and partner factors at the time of use; some frozen eggs will not survive thawing, some will not fertilize, and some embryos will not implant. Freezing is insurance in the ordinary sense—a hedge that improves options, not a policy that pays out automatically. Our egg-freezing guide covers the process, timing, and typical cost ranges in detail, including what a reserve evaluation adds to that decision.
13. Lifestyle and Supplements: The Honest Evidence
Patients diagnosed with low AMH are disproportionately targeted by supplement marketing, so a fair guide needs to draw the evidence line clearly. What has real support: not smoking (smoking is associated with lower AMH and earlier menopause in population studies, and cessation is worthwhile at any point), maintaining a healthy weight and metabolic health (insulin dynamics influence ovarian function, as the PCOS literature shows), and avoiding unnecessary delay when age or the plan argues for urgency. None of these raises the follicle count—the goal is protecting the function you have and keeping the rest of the system healthy.
What the evidence does not yet support: supplements that reliably raise AMH or “replenish” reserve. DHEA and CoQ10 are the two most commonly discussed—both have mixed small studies behind them, and ASRM committee guidance has consistently described the evidence as insufficient to recommend either for improving outcomes generally. They are not dangerous in typical doses for most people, and some physicians permit a time-limited trial while treatment proceeds—but nobody should spend six months taking capsules in place of getting evaluated. And one firm boundary: no diet, tea, or supplement reverses age-related decline. Reserve lost to time does not regenerate; the leverage lies in acting on the numbers you have today.
14. Frequently Asked Questions
What AMH level is considered low?
Commonly published reference ranges suggest values below roughly 1.0–1.2 ng/mL are consistent with diminished ovarian reserve, but cutoffs vary by laboratory assay and by age, and no single value is a diagnosis on its own. Your physician interprets the result alongside your antral follicle count, age, cycle history, and goals before it means anything actionable.
Can I get pregnant with low AMH?
Often yes. Low AMH reflects egg quantity, not quality, and it does not predict natural conception reliably—the STELLEC study found no reduced spontaneous-pregnancy probability associated with low AMH in women without infertility. What low values do change is planning: a structured evaluation and a clear timeline usually serve you better than open-ended waiting, particularly after 35.
Should I take DHEA or CoQ10 for low AMH?
Discuss it with your physician rather than starting on your own. Both supplements have mixed evidence, and professional guidance describes the data as insufficient to recommend them for improving outcomes broadly. They are generally safe in typical doses, but they are not a substitute for evaluation and treatment—and no supplement restores age-related decline.
Is a high AMH a good thing?
It depends on context. High values often accompany PCOS, where a large follicle pool coexists with irregular ovulation and an elevated risk of overstimulation during treatment. High AMH without symptoms is usually just an individual’s normal—but it deserves interpretation alongside cycles, ultrasound, and plans rather than being read as guaranteed fertility.
When should I have my AMH tested?
Reasonable triggers include: trying for 12 months without pregnancy (or 6 months if you are 35 or older); cycles that are irregular; a history of ovarian surgery, endometriosis, chemotherapy, or early menopause in close relatives; or—in your late twenties or thirties—simply wanting data to inform whether fertility preservation fits your plans. The test can be drawn on any cycle day.
15. Taking the Next Step
An AMH result is the beginning of a conversation, not the end of one. The evaluation that gives it meaning takes a single visit cycle: the AMH draw, an early-cycle ultrasound for antral follicle count, day-3 FSH and estradiol, thyroid and prolactin screening, and a partner’s semen analysis—assembled into a forecast of how your ovaries respond and a plan matched to your age and timeline. Whether the numbers point toward trying on your own a little longer, IUI, IVF, or fertility preservation, the decision should rest on your complete picture—explained in plain language, trade-offs included, and never reduced to a single alarming line on a lab printout. You can explore the full range of care at our fertility services overview.
Curious what your AMH means for your plans? Schedule a consultation with our fertility specialists in Torrance for a complete reserve evaluation—AMH, antral follicle count, and the full workup—and get your numbers interpreted in context, with a step-by-step plan to match.
Incinta Fertility Center — Fertility Clinic Torrance & South Bay, California. Patient-first care, bilingual support, and laboratory leadership you can trust.
